Bruce L. Levine

faculty photo
Barbara and Edward Netter Professor in Cancer Gene Therapy
Abramson Cancer Center of the University of Pennsylvania (Member), Abramson Cancer Center of the University of Pennsylvania (Member)
Director, Clinical Cell and Vaccine Production Facility , University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine and Abramson Cancer Center
Department: Pathology and Laboratory Medicine

Contact information
Center for Advanced Cell Therapies
South Tower, Building 421, 9th floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-898-9120
Graduate Group Affiliations
Education:
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
Permanent link
 

Description of Research Expertise

Immunology, Cell and Gene Therapy

Description of Other Expertise

Good Manufacturing Practices

Description of Itmat Expertise

Dr. Levine's interests include cell, gene, and biologic therapy clinical trial development, manufacturing, and testing and lymphocyte growth, activation and senescence.

Selected Publications

Lu Yunjie, Hippen Keli L, Lemire Amanda L, Gu Jian, Wang Weizhi, Ni Xuhao, Ranganathan Parvathi, Levine Bruce L, Riley James L, June Carl H, Turka Laurence A, Munn David H, Garzon Ramiro, Lu Ling, Blazar Bruce R: miR-146b antagomir treated human Tregs increase TRAF6-NFkB expression, suppressor function and GVHD inhibitory potency. Blood Aug 2016.

Teachey David T, Lacey Simon F, Shaw Pamela A, Melenhorst J Joseph, Maude Shannon L, Frey Noelle, Pequignot Edward, Gonzalez Vanessa E, Chen Fang, Finklestein Jeffrey, Barrett David M, Weiss Scott L, Fitzgerald Julie C, Berg Robert A, Aplenc Richard, Callahan Colleen, Rheingold Susan R, Zheng Zhaohui, Rose-John Stefan, White Jason C, Nazimuddin Farzana, Wertheim Gerald, Levine Bruce L, June Carl H, Porter David L, Grupp Stephan A: Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Cancer discovery 6(6): 664-79, June 2016.

Hexner Elizabeth O, Luger Selina M, Reshef Ran, Jeschke Grace R, Mangan James K, Frey Noelle V, Frank Dale M, Richman Lee P, Vonderheide Robert H, Aqui Nicole A, Rosenbach Misha, Zhang Yi, Chew Anne, Loren Alison W, Stadtmauer Edward A, Levine Bruce L, June Carl H, Emerson Stephen G, Porter David L: Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. American journal of hematology 91(5): 453-60, May 2016.

Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV: Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127(9): 1117, March 2016 Notes: doi: 10.1182/blood-2015-11-679134.

Grossman PM, Mohler ER 3rd, Roessler BJ, Wilensky RL, Levine BL, Woo EY, Upchurch GR Jr, Schneiderman J, Koren B, Hutoran M, Gershstein D, Flugelman MY: Phase I study of multi-gene cell therapy in patients with peripheral artery disease. Vascular Medicine 21(1): 21-32, February 2016.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JI, June CH, Le C, Weisdorf D, McGlave PB, Blazar BR, Wagner JE: Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile and clinical effect. Blood November 2015 Notes: ePub ahead of print, doi:10.1182/blood-2015-06-653667.

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine 7(303): 303ra139, September 2015 Notes: doi: 10.1126/scitranslmed.aac5415.

Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA: Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. New England Journal of Medicine 373(11): 1040-1047, September 2015.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH: NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine July 2015 Notes: doi:10.1038/nm.3910.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.: The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research 21(12): 2840-50, June 2015 Notes: DOI: 10.1158/1078-0432.CCR-14-2777

back to top
Last updated: 08/30/2016
The Trustees of the University of Pennsylvania